期刊文献+

单核苷酸多态性与华法林初始抗凝疗效和维持剂量的研究 预览 被引量:1

Research on single nucleotide polymorphism with initial anticoagulative effect and maintenance dose of Warfarin
在线阅读 下载PDF
分享 导出
摘要 目的筛选华法林初始抗凝治疗疗效和华法林维持剂量存在显著影响的基因因素。方法初始抗凝疗效组:选取进行心脏瓣膜置换的汉族患者212例,以术后4 d为观测期限,根据设立初始抗凝疗效的观测指标△INR4-1[即观测期结束时的国际标准化比值(INR)与初始INR的差值],筛选出对于该指标存在显著影响的基因因素。同时观查上述因素与其它终点事件如INR〉3、INR〉4和3 d内是否入窗等是否相关。维持剂量组:选取服用华法林3个月以上的门诊患者266例,需满足相隔7 d以上、在服用相同剂量华法林的情况下,2次INR检测结果均在治疗窗内。筛选显著影响的基因因素。结果在初始抗凝疗效组中,CYP2C9(rs1057910)、VKORC1(rs9923231)和VKORC1(rs2292566)对△INR4-1有明显影响;CYP2C9(rs1057910)和EPHX1(rs2292566)对3 d内INR是否进入治疗范围有明显影响(P〈0.001、P〈0.05)。在维持剂量组中,CYP2C9(rs1057910)和VKORC1(rs9923231)对每日及每周华法林剂量均有明显影响(P〈0.001)。结论 CYP2C9(rs1057910)、VKORC1(rs9923231)和EPHX1(rs2292566)对于华法林初始抗凝疗效有明显影响。CYP2C9(rs1057910)、VKORC1(rs9923231)对华法林维持剂量有明显影响。 Objective To screen genetic factors influencing Warfarin initial anticoagulative effect and maintenance dose. Methods A total of 212 Chinese Han mechanical heart valve replacement patients were enrolled as initial anticoagulative effect group. △INR4-1[the difference between international normalized ratio( INR) at the end of observation and initial INR] was used as an index to screen genetic factors during 4 d after their operations. The obtained results were needed to be identified whether they were associated with other endpoint events like overanticoagulation( INR〉 3 and INR 〉4) and time to first therapeutic INR in 3 d. In the maintenance dose group,266 Chinese Han outpatients who had been taking Warfarin for over 3 months were enrolled. Warfarin maintenance dose was defined as the dose that led to the patients' INR within the therapeutic range measured at least 7 d,which was used to screen genetic factors. Results In the initial anticoagulative effect group,CYP2C9( rs1057910),VKORC1( rs9923231) and VKORC1( rs2292566) were associated with △INR4-1( P〈0. 05),and CYP2C9( rs1057910) and EPHX1( rs2292566) were associated with time to first therapeutic INR( P〈0. 001,P〈0. 05). In the maintenance dose group,CYP2C9( rs1057910) and VKORC1( rs9923231) were associated with daily and weekly maintenance doses( P〈0. 05). Conclusions CYP2C9( rs1057910),VKORC1( rs9923231) and EPHX1( rs2292566) show strongly association with Warfarin initial anticoagulative effect. CYP2C9( rs1057910) and VKORC1( rs9923231) are significant factors for maintenance dose.
作者 吴炯 李军 邬升超 张春燕 宋斌斌 王蓓丽 郭玮 潘柏申 WU Jiong , LI Jun , WU Shengchao , ZHANG Chunyan , SONG Binbin , WANG Beili , GUO Wei , PAN Baishen ( 1. Department of Clinical Laboratory, Zhongshan Hospital, Fudan University School of Medicine, Shanghai 200032, China; 2. Cardial Surgery, Zhongshan Hospital, Fudan University School of Medicine, Shanghai 200032, China)
出处 《检验医学》 CAS 2015年第7期707-714,共8页 Laboratory Medicine
基金 “十二五”国家科技支撑计划资助项目(2012BAI37B01) 国家临床重点检验专科建设项目
关键词 华法林 单核苷酸多态性 初始抗凝疗效 维持剂量 Warfarin Single nucleotide polymorphism Initial anticoagulative effect Maintenance dose
作者简介 吴炯,男,1977年生,学士,主管技师,主要从事临床生化工作。 通讯作者:潘柏申,联系电话:021-640419902376。
  • 相关文献

参考文献16

  • 1WADELIUS M. Point: use of pharmacogenetics in guiding treatment with warfarin [J].Clin Chem, 2009, 55(4):709-711. 被引量:1
  • 2WADELIUS M,CHEN LY,ERIKSSON N,et al. Association of warfarin dose with genes involved in its action and metabolism [J].Hum Genet, 2007, 121(1):23-34. 被引量:1
  • 3GONG IY,TIRONA RG,SCHWARZ UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy[J]. Blood, 2011, 118(11): 3163-3171. 被引量:1
  • 4刘媛,钟诗龙,谭虹虹,杨敏,费洪文,余细勇,林曙光.CYP2C9与VKORC1基因变异对华法林初始抗凝治疗反应性的影响[J].中华心血管病杂志,2011,39(10):929-935. 被引量:8
  • 5娄莹,刘红,韩璐璐,谢爽,黄一玲,高小晶,段兵,柳志红,李一石.CYP2C9和VKORC1基因多态性对肺栓塞患者华法林初始抗凝疗效的影响[J].中国临床药理学杂志,2012,28(4):256-259. 被引量:20
  • 6CEN HJ, ZENF WT,LENG XY, et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement [J]. Br J Clin Pharmacol, 2010, 70(2): 234-240. 被引量:1
  • 7GU Q,KONG Y,SCHNEEDE J, et al. VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China [J]. Eur J Clin Pharmacol, 2010, 66(12): 1217-1227. 被引量:1
  • 8HUANG SW,XIANG DK,HUANG L, et al. Influence of GGCX genotype on warfarin dose requirements in Chinese patients [J]. Thromb Res, 2011, 127(2): 131-134. 被引量:1
  • 9KEALEY C,CHEN Z,CHRISTIE J, et al. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity [J]. Pharmacogenomics, 2007, 8(3): 217-225. 被引量:1
  • 10HIGASHI MK,VEENSTRA DL,KONDO LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy [J]. JAMA, 2002, 287(13): 1690-1698. 被引量:1

二级参考文献32

  • 1何震宇,孙丽敏,李月琴,潘伟,杨红.广东人群CYP2C9等位基因及基因型分布频率[J].广东医学,2006,27(8):1131-1132. 被引量:13
  • 2心房颤动抗栓研究协作组.华法林对非瓣膜病心房颤动抗栓的安全性和有效性研究.中华内科杂志,2006,45:800-803. 被引量:10
  • 3Ansell J,Hollowell J,Pengo V,et al.Descriptive analysis of the prosess and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atirial fibrillation:the international study of anticoagulation management (ISAM).J Thromb Thrombosis,2007,23:83-91. 被引量:1
  • 4Chiquette E,Amato MG,Bussey HI.Comparison of an anticoagulation clinic with usual medical care:anticoagulation control,patient outcomes,and health care costs.Arch Intern Med,1998,158:1641-1647. 被引量:1
  • 5Wittkowsky AK.Effective anticoagulation therapy:defining the gap between clinical studies and clinical practice.Am J Manag Care,2004,10:S297-S306. 被引量:1
  • 6Wittkowsky AK,Devine EB.Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin.Pharmacotherapy,2004,24:1311-1316. 被引量:1
  • 7Levine MN,Raskob G,Landefeld S,et al.Hemorrhagic complications of anticoagulant treatment.Chest,2001,119 (1Suppl):108S-121S. 被引量:1
  • 8Beyth R J,Quinn L,Landefeld CS.A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin:a randomized,controlled trial.Ann Intern Med,2000,133:687-695. 被引量:1
  • 9McMahan DA,Smith DM,Carey MA,et al.Risk of major hemorrhage for outpatients treated with warfarin.J Gen Intern Med,1998,13:311-316. 被引量:1
  • 10Takahashi H,Wilkinson GR,Padrini R,et al.CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin:similarities yet differences.Clin Pharmacol Ther,2004,75:376-380. 被引量:1

共引文献40

同被引文献15

引证文献1

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈